BED

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
月曜日, 5月 6, 2024
Shift, Migraine, FDA, Agitation, Research, EMERGE, Webcast, CNS, Prescription, Reboxetine, Privacy, Medicine, BED, Obstructive sleep apnea, Fibromyalgia, Shift work, Deficit spending, Food, Sleep, System, ADHD, SWD, SYMPHONY, NT1, Therapy, Quality of life, Food and Drug Administration, MDD, Narcolepsy Network, Shirin David, Patient, Somnolence, FOCUS, Safety, Depression, CGRP, Binge eating disorder, Medicare, Cataplexy, Central nervous system, Government, DSM-IV codes, Clinical trial, EDS, NDA, NMDA, GPO, Psychiatry, MD, Idiopathic hypersomnia, Smoking, CMAI, Pivotal, Breakthrough therapy, Growth, Pharmaceutical industry

Auvelity net product sales were $53.4 million for the first quarter of 2024, representing 240% year-over-year growth.

Key Points: 
  • Auvelity net product sales were $53.4 million for the first quarter of 2024, representing 240% year-over-year growth.
  • Total cost of revenue was $6.3 million for the first quarter of 2024.
  • Research and development (R&D) expenses were $36.8 million for the first quarter of 2024, compared to $17.8 million for the comparable period in 2023, respectively.
  • Approximately 95,000 prescriptions were written for Auvelity in the first quarter of 2024, representing a 12% sequential increase versus the fourth quarter of 2023.

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Retrieved on: 
月曜日, 4月 1, 2024
Central nervous system, Binge eating disorder, Patient, CNS, BED, Therapy, Safety, Pharmaceutical industry

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults.

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults.
  • ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of BED in adults.
  • Approximately 450 patients will be randomized in a 1:1:1 ratio to receive solriamfetol (150 or 300 mg) or placebo for 12 weeks.
  • The first patient was screened in the ENGAGE trial in March 2024.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
火曜日, 2月 20, 2024
Shift, Acquisition, DSM-IV codes, Fibromyalgia, Central nervous system, Total, New Drug Application, MD, Narcolepsy, FDA, Marketing, Smoking, Food, Somnolence, Growth, SYMPHONY, Reboxetine, Psychiatry, Dextromethorphan/bupropion, Migraine, FOCUS, Safety, Therapy, Medicare, NMDA, CNS, Food and Drug Administration, BED, Webcast, Depression, Binge eating disorder, Patient, Agitation, Shirin David, Medicaid, SWD, Breakthrough therapy, MDD, NDA, Prescription, Pharmaceutical industry

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.

Monte Nido & Affiliates Provides Education on Binge Eating Disorder for National Eating Disorders Awareness Week

Retrieved on: 
火曜日, 2月 13, 2024
Binge eating disorder, Eating, Doctor of Philosophy, Weight loss, Body image, Argyreia nervosa, MBA, Food, Guilt, Network affiliate, BED, National Eating Disorders Association, Eating disorder, Diagnosis, Blame, Dietary supplement

MIAMI, Feb. 13, 2024 /PRNewswire/ -- Nearly 29 million Americans will experience an eating disorder in their lifetime, and only one in 10 will get the care they need. Eating Disorders Awareness Week, Feb. 26 – March 3, aims to raise awareness about eating disorders and support those affected by them. Monte Nido & Affiliates, one of the largest and leading eating disorder treatment providers in the country, provides vital treatment and resources for those who may be struggling with an eating disorder themselves or have concerns about a loved one.

Key Points: 
  • Eating Disorders Awareness Week, Feb. 26 – March 3, aims to raise awareness about eating disorders and support those affected by them.
  • Monte Nido & Affiliates , one of the largest and leading eating disorder treatment providers in the country, provides vital treatment and resources for those who may be struggling with an eating disorder themselves or have concerns about a loved one.
  • "This year, we are focused on driving awareness of binge eating disorder, which remains relatively unknown despite affecting millions of Americans.
  • Binge eating disorder (BED) is the most common eating disorder in the U.S., affecting more people than anorexia and bulimia combined.

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

Retrieved on: 
木曜日, 12月 7, 2023
Sleep medicine, Psychiatry, Attention deficit hyperactivity disorder, Obstructive sleep apnea, Eastern Time Zone, Division, Binge eating disorder, TAAR1, Psychopharmacology, BED, SHARP, Medical school, DSM-IV codes, MD, Doctor of Philosophy, Research, Therapy, University, HOPE, Associate, EDS, CNS, Narcolepsy, OSA, Webcast, Central nervous system, MDD, Patient, ADHD, Harvard Medical School, Dopamine, SWD

At the event, invited physician thought leaders will discuss current and potential future indications.

Key Points: 
  • At the event, invited physician thought leaders will discuss current and potential future indications.
  • The Axsome senior leadership team will provide an overview of clinical development plans.
  • Expert thought leaders presenting at the event include:
    Craig Chepke, MD, Medical Director of Excel Psychiatric Associates in Huntersville, N.C. and Adjunct Associate Professor of Psychiatry for Atrium Health.
  • A replay of the webcast will be available for approximately 30 days following the live event.

GT Medical Technologies, Inc. Presents Use of GammaTile Therapy is Increasing in Time Across Several Brain Tumor Types at the 28th Annual Scientific Meeting and Education Day at the Society of Neuro-Oncology (SNO)

Retrieved on: 
金曜日, 11月 17, 2023
Quality, Education, Radiation, Treatment, Brain metastasis, Seed, Glioblastoma, Brain, Convention, Patient, Abstract, Caesium, Pakistan Society of Neuro-Oncology, FDA, Quality of life, Meningioma, BED, Neuro, Cancer, Metastasis, Radiosurgery, Doctor of Philosophy, Neoplasm, Use, Society, Poster, SNO, Medical physics, Medical imaging, Glioma

TEMPE, Ariz., Nov. 17, 2023 /PRNewswire/ -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced an increase of clinical cases in the United States using its GammaTile® Therapy in patients diagnosed with several brain tumor types. The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.

Key Points: 
  • The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.
  • GammaTile has been used in over 1,000 patients with both newly diagnosed malignant brain tumors and recurrent brain tumors since 2019 and has been used in different tumor types, including glioblastoma, brain metastasis and meningioma.
  • Currently, GammaTile is sponsoring 4 clinical trials including a multi-institute registry trial (NCT0442738) that includes quality of life as a study metric.
  • GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) that delivers immediate radiation and eradicates brain tumor cells before they can replicate post-surgery while helping to protect healthy brain tissue.

TAG Oil Provides Update on BED4-T100 Well Drilling Operations

Retrieved on: 
水曜日, 11月 15, 2023
OTCQX, BED, TAG Oil, T100, Abu Rawash, ARF, Natural gas

VANCOUVER, BC, Nov. 15, 2023 /PRNewswire/ - TAG Oil Ltd. (TSXV: TAO) (OTCQX: TAOIF) ("TAG Oil" or the "Company") would like to provide the following update on drilling progress of the BED4-T100 ("T100") horizontal well in the Badr Oil Field ("BED-1") in the Western Desert of Egypt.

Key Points: 
  • VANCOUVER, BC, Nov. 15, 2023 /PRNewswire/ - TAG Oil Ltd. (TSXV: TAO) (OTCQX: TAOIF) ("TAG Oil" or the "Company") would like to provide the following update on drilling progress of the BED4-T100 ("T100") horizontal well in the Badr Oil Field ("BED-1") in the Western Desert of Egypt.
  • Initial drilling of the ARF unconventional, carbonate formation performed well at smooth build angles and steadily increasing drilling rates.
  • Drilling has commenced from the intermediate cased section at about 2,800 meters and is projected to be completed in December.
  • TAG Oil will continue to provide regular drilling updates, as necessary.

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
月曜日, 11月 6, 2023
Shift, Research, AD, Food, Medicare, FOCUS, Narcolepsy, Doctor of Philosophy, Fibromyalgia, Prescription, New Drug Application, Agitation, Shift work, Shirin David, Physician, SG, Acquisition, Smoking, Amgen, Webcast, Somnolence, NDA, Safety, Therapy, Patient, Food and Drug Administration, Central nervous system, Eli Lilly and Company, Reboxetine, SWD, ES, MD, Migraine, Growth, Binge eating disorder, Breakthrough therapy, Total, FDA, Government, SYMPHONY, CMC, CNS, R, DSM-IV codes, Horizon Therapeutics, BED, Dextromethorphan/bupropion, NMDA, Eating disorder, Beauty salon, Video game, Pharmaceutical industry, Bank, Dietary supplement, Solriamfetol, ADHD, Medicaid

“Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.

Key Points: 
  • “Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.
  • Auvelity® net product sales were $37.7 million for the third quarter of 2023, representing a 36% sequential increase versus the second quarter of 2023.
  • Third quarter 2023 U.S. Sunosi total prescriptions increased by 16% versus the third quarter of 2022, and sequentially by 5% versus the second quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss third quarter 2023 financial results as well as to provide a corporate update.

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
月曜日, 8月 7, 2023
Shift, Total, Migraine, Central nervous system, Narcolepsy, SG, SWD, Eating disorder, Binge eating disorder, FOCUS, New Drug Application, Food and Drug Administration, DCC, NDA, Prescription, NMDA, SYMPHONY, CNS, Government, ES, Medicare, Breakthrough therapy, MD, Physician, Patient, Esreboxetine, Reboxetine, BED, Fibromyalgia, Somnolence, Webcast, R, Research, AD, FDA, Therapy, Smoking, Dextromethorphan/bupropion, Agitation, Food, Safety, Pharmaceutical industry, Video game, Bank, Security (finance), Dietary supplement, Medicaid, Solriamfetol, ADHD

Auvelity® net product sales were $27.6 million for the second quarter of 2023, representing a 76% sequential increase versus the first quarter of 2023.

Key Points: 
  • Auvelity® net product sales were $27.6 million for the second quarter of 2023, representing a 76% sequential increase versus the first quarter of 2023.
  • Approximately 53,000 prescriptions were reported for Auvelity in the second quarter of 2023, representing a 72% sequential increase versus the first quarter of 2023.
  • Second quarter 2023 U.S. Sunosi total prescriptions increased by 15% versus the second quarter of 2022, and sequentially by 8% versus the first quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss first quarter 2023 financial results as well as to provide a corporate update.

TAG Oil Reports FY2023 Results and Provides Corporate Update

Retrieved on: 
月曜日, 7月 31, 2023
OTCQX, API, TAG Oil, ARF, T100, BED, Bank statement, SEDAR, Cryptocurrency

VANCOUVER, BC, July 31, 2023 /PRNewswire/ - TAG Oil Ltd. (TSXV: TAO ) and (OTCQX: TAOIF ) ("TAG Oil" or the "Company") is pleased to report the filing of its financial results for the fiscal year ending March 31, 2023.

Key Points: 
  • VANCOUVER, BC, July 31, 2023 /PRNewswire/ - TAG Oil Ltd. (TSXV: TAO ) and (OTCQX: TAOIF ) ("TAG Oil" or the "Company") is pleased to report the filing of its financial results for the fiscal year ending March 31, 2023.
  • TAG Oil continues to manage its costs and allocate the necessary resources towards its business development efforts in Egypt and other areas in the Middle East and North Africa ("MENA") region.
  • Since the BED 1-7 well started production cumulative oil production from the well to date is over 6,000 barrels of 23-degree API oil.
  • TAG Oil also announces the grant of 1,800,000 stock options that are exercisable for a period of five years at a price of C$0.70 per share to various staff members, and certain officers and directors.